Published in Lab Law Weekly, June 23rd, 2006
This trend article about Free University of Amsterdam is an immediate alert from LawRx to identify developing directions of research.
Study 1: The evaluation of risks and benefits of phase II cancer clinical trials by institutional review board (IRB) members was assessed.
According to recent research from the Netherlands, "There are indications that institutional review board (IRB) members do not find it easy to assess the risks and benefits in medical experiments, although this is their principal duty. This study examined how IRB members assessed the risk/benefit...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.